SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,100,261,770 |
| Positions | 12 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| PARABILIS MEDICINES INC | PBLS | COM | $175,517,789 | 6,412,780 |
| BEAM THERAPEUTICS INC | BEAM | COM | $155,771,929 | 4,540,132 |
| RAPPORT THERAPEUTICS INC | RAPP | COM | $155,376,512 | 3,728,738 |
| SEAPORT THERAPEUTICS INC | SPTX | COMMON STOCK | $136,600,437 | 6,294,951 |
| ERASCA INC | ERAS | COM | $129,917,324 | 7,091,557 |
| VIR BIOTECHNOLOGY INC | VIR | COM | $129,353,521 | 12,694,163 |
| MAZE THERAPEUTICS INC | MAZE | COM | $122,983,582 | 4,120,053 |
| LYELL IMMUNOPHARMA INC | LYEL | COM NEW | $45,525,211 | 3,247,162 |
| GENERATE BIOMEDICINES INC | GENB | COM SHS | $32,802,467 | 1,944,426 |
| 10X GENOMICS INC | TXG | CL A COM | $8,351,756 | 217,834 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.